The Varicella Zoster (HHV-3) Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Varicella Zoster (HHV-3) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Varicella Zoster (HHV-3) Infections. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Varicella Zoster (HHV-3) Infections and features dormant and discontinued products.

GlobalData tracks 68 drugs in development for Varicella Zoster (HHV-3) Infections by 61 companies/universities/institutes. The top development phase for Varicella Zoster (HHV-3) Infections is preclinical with 28 drugs in that stage. The Varicella Zoster (HHV-3) Infections pipeline has 65 drugs in development by companies and three by universities/ institutes. Some of the companies in the Varicella Zoster (HHV-3) Infections pipeline products market are: Beijing Minhai Biotechnology, Pfizer and GSK.

The key targets in the Varicella Zoster (HHV-3) Infections pipeline products market include Interferon Alpha/Beta Receptor 1 (Cytokine Receptor Class II Member 1 or Cytokine Receptor Family 2 Member 1 or Type I Interferon Receptor 1 or IFNAR1), Interferon Alpha/Beta Receptor 2 (Interferon Alpha Binding Protein or Type I Interferon Receptor 2 or IFNAR2), and Varicella zoster virus Envelope glycoprotein E (gE).

The key mechanisms of action in the Varicella Zoster (HHV-3) Infections pipeline product include Interferon Alpha/Beta Receptor 1 (Cytokine Receptor Class II Member 1 or Cytokine Receptor Family 2 Member 1 or Type I Interferon Receptor 1 or IFNAR1) Agonist with five drugs in Phase III. The Varicella Zoster (HHV-3) Infections pipeline products include five routes of administration with the top ROA being Intramuscular and 12 key molecule types in the Varicella Zoster (HHV-3) Infections pipeline products market including Subunit Vaccine, and mRNA Vaccine.

Varicella Zoster (HHV-3) Infections overview

Varicella-zoster virus (VZV), also known as human herpesvirus 3 (HHV-3), causes two distinct infections: chickenpox (varicella) and shingles (herpes zoster). Varicella is a highly contagious viral infection characterized by an itchy rash with red spots and fluid-filled blisters that break open and form scabs. It spreads through respiratory droplets and direct contact with the rash. Varicella commonly affects children, and symptoms besides the rash include fever, fatigue, and loss of appetite. The illness usually resolves within 1-2 weeks. However, after the primary infection of chickenpox, VZV can remain dormant in nerve cells. Later in life or when the immune system weakens, the virus may reactivate, causing shingles. Shingles manifests as a painful rash that typically appears on one side of the body, often in a band-like pattern along a nerve pathway. Other symptoms may include burning, tingling, or shooting pain. It usually lasts for several weeks.

For a complete picture of Varicella Zoster (HHV-3) Infections’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.